RA Capital Healthcare Fund LP 的 Form 4 申報
Bambusa Therapeutics, Inc.BBTX,2026/11/3 申報
- 申報編號
- 0001231919-26-001533
- 申報時間
- 2026/11/3 18:09 ET
- 交易日
- 2026/10/30-11/2
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 6 筆非衍生性交易、4 筆衍生性交易。公開市場買進合計 $4,664 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | 董事、持股 10% 以上大股東 |
| Ra Capital Management, L.P.CIK 0001346824 | 董事、持股 10% 以上大股東 |
| Kolchinsky PeterCIK 0001384859 | 董事、持股 10% 以上大股東 |
| Shah Rajeev M.CIK 0001619841 | 董事、持股 10% 以上大股東 |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | 董事 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/10/30 | Common Stock | P買進取得 | +189,909 | $14.23F1 | +$2,702,405.07 | 189,909 | 間接 | |
| 2026/10/30 | Common Stock | P買進取得 | +263,911 | $14.92F4 | +$3,937,552.12 | 453,820 | 間接 | |
| 2026/11/2 | Common Stock | C轉換取得 | +3,144,858 | –F5 | – | 3,598,678 | 間接 | |
| 2026/11/2 | Common Stock | C轉換取得 | +1,331,080 | –F5 | – | 1,331,080 | 間接 | |
| 2026/11/2 | Common Stock | P買進取得 | +2,335,109 | $16.00 | +$37,361,744 | 5,933,787 | 間接 | |
| 2026/11/2 | Common Stock | P買進取得 | +164,891 | $16.00 | +$2,638,256 | 1,495,971 | 間接 |
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/2 | Common Stock | C轉換處分 | −2,844,910 | $0.00 | $0 | 0 | 間接 | |
| 2026/11/2 | Common Stock | C轉換處分 | −1,278,148 | $0.00 | $0 | 0 | 間接 | |
| 2026/11/2 | Common Stock | C轉換處分 | −299,948 | $0.00 | $0 | 0 | 間接 | |
| 2026/11/2 | Common Stock | C轉換處分 | −52,932 | $0.00 | $0 | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
表 I 有 2 筆交易的價格引用這則附註。
備註
Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.